Compare Prologis Inc (PLD) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prologis Inc vs Repligen Corporation Common Stock — how do they compare? Prologis Inc trades at $131.3 (market cap $126.92B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Prologis Inc is far larger — about 11.4× Repligen Corporation Common Stock's market cap, and Prologis Inc pays a 3.2% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prologis Inc for 102 Days and Repligen Corporation Common Stock for 0 Days on average.
| PLD | RGEN | |
|---|---|---|
Market Cap | $126.92B | $11.14B |
Volume | 4,456,134 | 1,259,263 |
Sector | Real Estate | Health |
52-Week High | $149.96 | $194.57 |
52-Week Low | $121.17 | $102.87 |
Typical Hold Time | 102 Days | 0 Days |
Enterprise Value | $161.66B | $11.02B |
Dividend Yield | 3.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prologis (PLD) trades at $130.53, down 1.46% on the day, with strong fundamentals including 45.79% net income margin and consistent earnings beats. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages, trading near support at $130. Recent news highlights leasing growth and data center expansion opportunities, while institutional buying continues.
Outlook remains positive with 61.9% analyst buy ratings and $155.15 consensus target offering 19% upside. Key risks include elevated valuation multiples (P/E 29.74) and rising debt-to-asset ratio (37.2% in 2025). The company's logistics real estate portfolio benefits from e-commerce and data center demand trends.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
